JP2010534061A5 - - Google Patents

Download PDF

Info

Publication number
JP2010534061A5
JP2010534061A5 JP2010517023A JP2010517023A JP2010534061A5 JP 2010534061 A5 JP2010534061 A5 JP 2010534061A5 JP 2010517023 A JP2010517023 A JP 2010517023A JP 2010517023 A JP2010517023 A JP 2010517023A JP 2010534061 A5 JP2010534061 A5 JP 2010534061A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
protein
protease
fusion protein
activation domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010517023A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010534061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/008786 external-priority patent/WO2009014650A2/en
Publication of JP2010534061A publication Critical patent/JP2010534061A/ja
Publication of JP2010534061A5 publication Critical patent/JP2010534061A5/ja
Withdrawn legal-status Critical Current

Links

JP2010517023A 2007-07-20 2008-07-18 組換えコレラ菌外毒素 Withdrawn JP2010534061A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96130807P 2007-07-20 2007-07-20
PCT/US2008/008786 WO2009014650A2 (en) 2007-07-20 2008-07-18 Recombinant vibrio cholerae exotoxins

Publications (2)

Publication Number Publication Date
JP2010534061A JP2010534061A (ja) 2010-11-04
JP2010534061A5 true JP2010534061A5 (enExample) 2011-09-01

Family

ID=40282021

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010517023A Withdrawn JP2010534061A (ja) 2007-07-20 2008-07-18 組換えコレラ菌外毒素

Country Status (4)

Country Link
US (1) US8524241B2 (enExample)
EP (1) EP2178559B1 (enExample)
JP (1) JP2010534061A (enExample)
WO (1) WO2009014650A2 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE524489T1 (de) * 2005-07-29 2011-09-15 Us Gov Health & Human Serv Mutierte pseudomonas-exotoxine mit reduzierter antigenität
EP2046375B1 (en) * 2006-07-20 2017-04-05 The General Hospital Corporation Methods and compositions for the selective activation of protoxins through combinatorial targeting
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US20110250199A1 (en) * 2008-06-04 2011-10-13 The Government of the United States of America as represented by the Secretary of the Department.... Immunotoxins and uses thereof
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US20130122043A1 (en) * 2010-04-20 2013-05-16 Whitehead Institute For Biomedical Research Modified polypeptides and proteins and uses thereof
AU2011302645B2 (en) 2010-09-15 2015-02-26 Applied Molecular Transport, Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP2730289A1 (en) * 2012-11-07 2014-05-14 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel immunoproteases
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
EP3139965B1 (en) 2014-05-07 2021-09-29 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
WO2016146833A1 (en) * 2015-03-19 2016-09-22 F. Hoffmann-La Roche Ag Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016207324A1 (en) * 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Biomarkers for nad(+)−diphthamide adp ribosyltransferase sensitivity and resistance
CN106478773B (zh) * 2015-08-25 2021-09-14 三生国健药业（上海）股份有限公司 一种人工合成的新型信号肽
EP3419670A2 (en) 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
SG11202104734YA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Cholix-derived carriers for oral delivery of heterologous payload
ES2911075T3 (es) * 2018-11-07 2022-05-17 Applied Molecular Transport Inc Constructos de administración para transcitosis y métodos relacionados
CN114555791B (zh) * 2019-08-13 2026-07-14 伦敦国王学院 Il-1超家族时空限制性活性细胞因子铠装的免疫应答细胞
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
EP4380973A2 (en) 2021-08-02 2024-06-12 Yeda Research and Development Co. Ltd. Anti-matrix metalloproteinase-14 antibodies for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US6051405A (en) * 1986-09-24 2000-04-18 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Constructs encoding recombinant antibody-toxin fusion proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2665827B2 (ja) 1990-05-11 1997-10-22 アメリカ合衆国 低―動物毒性と高殺細胞活性の改良シュードモナス外毒素
US6099842A (en) 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
CA2136724A1 (en) 1992-06-18 1993-12-23 Ira H. Pastan Recombinant pseudomonas exotoxin with increased activity
US6426075B1 (en) 1996-11-06 2002-07-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Protease-activatable pseudomonas exotoxin A-like proproteins
US6086900A (en) 1997-03-26 2000-07-11 Board Of Regents, The University Of Texas Systems Methods and compositions for using membrane-penetrating proteins to carry materials across cell membranes
US6566500B1 (en) 1999-03-30 2003-05-20 Board Of Regents, The University Of Texas System Compositions and methods for modifying toxic effects of proteinaceous compounds
US7585942B2 (en) 2003-11-25 2009-09-08 Anjin Corporation Diphtheria toxin variant
US7550426B2 (en) * 2005-05-18 2009-06-23 Ghc Research Development Corporation Acetylated therapeutic procytotoxins
EP2046375B1 (en) 2006-07-20 2017-04-05 The General Hospital Corporation Methods and compositions for the selective activation of protoxins through combinatorial targeting
US20110250199A1 (en) * 2008-06-04 2011-10-13 The Government of the United States of America as represented by the Secretary of the Department.... Immunotoxins and uses thereof

Similar Documents

Publication Publication Date Title
Cooper et al. Soluble CD23 controls IgE synthesis and homeostasis in human B cells
Skidgel et al. Cellular carboxypeptidases
Cruz‐Garcia et al. Stylar glycoproteins bind to S‐RNase in vitro
Sato et al. Further studies on the site-specific protein modification by microbial transglutaminase
WO2023155901A1 (en) Mutant cytidine deaminases with improved editing precision
HRP20191305T1 (hr) Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
JP2022109971A (ja) 細胞および組織への遺伝子編集タンパク質および組成物の、ベクターなしでの送達
NZ602351A (en) Axmi-115, axmi-113, axmi-005, axmi-163 and axmi-184 : vip3a insecticidal proteins from bacillus thuringiensis and methods for their use
Fath et al. Association of yeast RNA polymerase I with a nucleolar substructure active in rRNA synthesis and processing
BRPI0612273A2 (pt) anticorpo de ligaÇço a il-1 beta ou fragmento de ligaÇço a il-1 beta do mesmo, Ácido nucleico, vetor, cÉlula, animal transgÊnico, hibridoma, composiÇço, e, mÉtodos de tratamento ou prevenÇço de uma doenÇa ou doenÇa relacionada a il-1 em um mamÍfero, e de preparaÇço de um polipeptÍdeo de ligaÇço a il-1 beta maturado por afinidade
Basu et al. A novel S100A8/A9 induced fingerprint of mesenchymal stem cells associated with enhanced wound healing
BRPI1012321A8 (pt) Anticorpos anti-vegf e seus usos
US20100016549A1 (en) Peyer's patch and/or m-cell targeting ligands
Herhaus et al. The emerging roles of deubiquitylating enzymes (DUBs) in the TGFβ and BMP pathways
NZ596981A (en) Compositions and methods for the treatment of tumor of hematopoietic origin
CN112654702A (zh) 改进的核酸酶的组合物和方法
Lipinszki et al. Ubiquitylation of Drosophila p54/Rpn10/S5a regulates its interaction with the UBA–UBL polyubiquitin receptors
Riffer et al. Mutational analysis of K28 preprotoxin processing in the yeast Saccharomyces cerevisiae
NZ589806A (en) Variant hedgehog-interacting protein (hhip1) and methods and uses thereof
Martinić Cezar et al. Enhancing Yeast Surface Display: UPR, ERAD, and ER Dynamics in Recombinant Protein Production
Karki et al. Intracellular trafficking and glycosylation of hydroxyproline-O-glycosylation module in tobacco BY-2 cells is dependent on medium composition and transcriptome analysis
RU2008153051A (ru) Способ направленной доставки днк в опухолевые и стволовые клетки
JP5872472B2 (ja) シャペロニン１０変異体
KR20250051673A (ko) 높은 hdr 비율을 달성하는 데 필요한 aav의 양을 감소시키는 53bp1 결합에 대한 친화도가 높은 유비퀴틴 변이체
Matsumoto et al. Tenascin-C expression and splice variant in habu snake venom-induced glomerulonephritis